Drug Profile
C 3193
Latest Information Update: 31 Jan 2008
Price :
$50
*
At a glance
- Originator Merck & Co
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 31 Dec 2004 Phase-II clinical trials in Chronic obstructive pulmonary disease (unspecified route)
- 11 Mar 2004 Phase-I clinical trials in Chronic obstructive pulmonary disease (unspecified route)